New Reference: Bretuximab Vedotin in Stage III-IV Hdogkin Lymphoma
Study
Multicenter, randomized, open-label trial
|
Stage 3 or 4 advanced Hodgkin’s lymphoma
|
A+AVD (n:664) or ABVD (n:670)
|
Efficacy
OS favored A+AVD over ABVD (HR: 0.59; P=0.009)
|
6 year OS: 93.9% (95% CI, 91.6 to 95.5) vs 89.4% (95% CI, 86.6 to 91.7)
|
6 year PFS: 82.3% and 74.5%, HR:0.68; 95% CI, 0.53 to 0.86)
|
Safety
Completed all treatment: 89.3% vs 90.7%
|
Any cause related death: 39 vs 64 patients
|
Hodgkin Lymphoma related death: 32 vs 45 patients
|
Second cancer related death: 1 vs 11 patients
|
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022
